Natera (NTRA.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow - Longbridge

Quote List Quote List

Event Tracking

Dec18

Natera Inc. Publishes Study Results on Celecoxib Combined with Chemotherapy Lowering CRC Recurrence and Mortality Risk

15:38

Dec17

Natera Inc Official Discloses Stock Ownership Change

02:16

Natera Director Herm Rosenman Disposed of Common Stock

02:05

Dec16

Jefferies analyst reiterates buy rating on Natera with a target price of $275

15:22

Natera Inc. Announces Improvement in Early High-Risk Breast Cancer Recurrence Risk Assessment with Signatera™ ctDNA Test

13:02

Dec13

Stanley Druckenmiller's Dukus Family Office Increases Stake in Natera Inc.

15:46

Schedules & Filings

Schedules

Filings

Nov6

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 592.18 M, Net Income -87.54 M, EPS -0.6381

Aug7

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 546.6 M, Net Income -100.94 M, EPS -0.74

May8

Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 501.83 M, Net Income -66.94 M, EPS -0.4967

View More

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change

View More